Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Consolidated Statements of Operations
Grant and award revenue	$ 789	$ 491
Operating expenses
Research and development	6,111	5,429
General and administrative	3,463	3,253
Total operating expenses	9,574	8,682
Operating loss	(8,785)	(8,191)
Other income (expense)
Interest income	60	59
Interest expense	(5,559)	(3,602)
Change in fair value of the Convertible Loan	(101,062)	5,203
Total other income (expense), net	(106,561)	1,660
Net loss	$ (115,346)	$ (6,531)
Per share information:
Net loss per share, basic	$ (3.16)	$ (0.18)
Weighted average shares outstanding, basic	36,530,284	36,184,802
Net loss per share, diluted	$ (3.16)	$ (0.2)
Weighted average shares outstanding, diluted	36,530,284	59,478,662